In Vitro Inhibitory Effect of Nigella sativa L. Extracts on SARS-COV-2 Spike Protein-ACE2 Interaction

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2024-01-01 DOI:10.1016/j.curtheres.2024.100759

Najma Ali , Asha Caroline Cyril , Anagha Parambath , Cijo George Vazhappilly , Reem Kais Jan , Haneen Aburamadan , Fatemeh Akbarpoor , S. M. Shariar Islam , Fazilatun Nessa , Yosra Lozon , Noushad Karuvantevida , Rajan Radhakrishnan

{"title":"In Vitro Inhibitory Effect of Nigella sativa L. Extracts on SARS-COV-2 Spike Protein-ACE2 Interaction","authors":"Najma Ali , Asha Caroline Cyril , Anagha Parambath , Cijo George Vazhappilly , Reem Kais Jan , Haneen Aburamadan , Fatemeh Akbarpoor , S. M. Shariar Islam , Fazilatun Nessa , Yosra Lozon , Noushad Karuvantevida , Rajan Radhakrishnan","doi":"10.1016/j.curtheres.2024.100759","DOIUrl":null,"url":null,"abstract":"<div><h3>Ethnopharmacological relevance</h3><div>A catastrophic outbreak of severe acute respiratory syndrome (SARS-CoV-2; Coronavirus disease-19; COVID-19) was first detected in Wuhan, Hubei Province, China, in December 2019. Many experimental and clinical studies have focused on the effectiveness of medicinal plants such as <em>Nigella sativa</em> (NS) in combating SARS-CoV-2. In this study, we aimed to evaluate the <em>in vitro</em> effect of NS seed extract on SARS-CoV-2 spike protein (S1)-angiotensin-converting enzyme 2 (S-ACE2) interaction.</div></div><div><h3>Materials and methods</h3><div>NS seed extracts used for the assay were prepared in chloroform, ethanol, and water by Soxhlet extraction and recovered by rotary evaporation. The inhibition percentage of S1-ACE2 interaction was analyzed using ELISA-SARS-CoV-2 S1 Protein-ACE2 Binding Inhibitor Screening Kit. Chemical finger-printing of the extracts was done using RP-HPLC.</div></div><div><h3>Results</h3><div>Significant concentration-dependent inhibition of the S1-ACE2 interaction was observed with chloroform, ethanol, and water extracts, ranging from 0.01 to 10 mg/ml. The <em>P</em>-values for the extracts were as follows: 0.0055, 0.0937, 0.0013, and 0.0003 for chloroform extract; 0.0876, 0.0703, 0.0183, and 0.0071 for ethanol extract; and 0.0915, 0.0312, 0.0006, and 0.0006 for water extract. The 50% inhibitory concentration (IC50) was determined to be 0.132 mg/ml, 0.288 mg/ml, and 4.06 mg/ml for chloroform, ethanol, and water extracts, respectively.</div></div><div><h3>Conclusion</h3><div>The <em>in vitro</em> analysis utilizing SARS-CoV2 spike (S1) and ACE2 proteins proved that NS seed extracts have the potential to inhibit the S-ACE2 interaction, which warrants further studies that could lead to potential drug discovery for SARS-CoV2 infection.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"101 ","pages":"Article 100759"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X24000298","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Ethnopharmacological relevance

A catastrophic outbreak of severe acute respiratory syndrome (SARS-CoV-2; Coronavirus disease-19; COVID-19) was first detected in Wuhan, Hubei Province, China, in December 2019. Many experimental and clinical studies have focused on the effectiveness of medicinal plants such as Nigella sativa (NS) in combating SARS-CoV-2. In this study, we aimed to evaluate the in vitro effect of NS seed extract on SARS-CoV-2 spike protein (S1)-angiotensin-converting enzyme 2 (S-ACE2) interaction.

Materials and methods

NS seed extracts used for the assay were prepared in chloroform, ethanol, and water by Soxhlet extraction and recovered by rotary evaporation. The inhibition percentage of S1-ACE2 interaction was analyzed using ELISA-SARS-CoV-2 S1 Protein-ACE2 Binding Inhibitor Screening Kit. Chemical finger-printing of the extracts was done using RP-HPLC.

Results

Significant concentration-dependent inhibition of the S1-ACE2 interaction was observed with chloroform, ethanol, and water extracts, ranging from 0.01 to 10 mg/ml. The P-values for the extracts were as follows: 0.0055, 0.0937, 0.0013, and 0.0003 for chloroform extract; 0.0876, 0.0703, 0.0183, and 0.0071 for ethanol extract; and 0.0915, 0.0312, 0.0006, and 0.0006 for water extract. The 50% inhibitory concentration (IC50) was determined to be 0.132 mg/ml, 0.288 mg/ml, and 4.06 mg/ml for chloroform, ethanol, and water extracts, respectively.

Conclusion

The in vitro analysis utilizing SARS-CoV2 spike (S1) and ACE2 proteins proved that NS seed extracts have the potential to inhibit the S-ACE2 interaction, which warrants further studies that could lead to potential drug discovery for SARS-CoV2 infection.

查看原文本刊更多论文

Nigella sativa L.提取物对SARS-COV-2尖峰蛋白-ACE2相互作用的体外抑制作用

民族药理学意义2019年12月，中国湖北省武汉市首次发现严重急性呼吸系统综合征（SARS-CoV-2；冠状病毒病-19；COVID-19）灾难性爆发。许多实验和临床研究都关注药用植物如黑麦草（NS）在抗击SARS-CoV-2方面的功效。材料与方法NS种子提取物分别用氯仿、乙醇和水进行索氏提取，旋转蒸发回收。使用 ELISA-SARS-CoV-2 S1 蛋白-ACE2 结合抑制剂筛选试剂盒分析 S1-ACE2 相互作用的抑制率。结果氯仿、乙醇和水提取物对 S1-ACE2 相互作用的抑制作用具有显著的浓度依赖性，浓度范围为 0.01 至 10 mg/ml。提取物的 P 值如下氯仿提取物的 P 值分别为 0.0055、0.0937、0.0013 和 0.0003；乙醇提取物的 P 值分别为 0.0876、0.0703、0.0183 和 0.0071；水提取物的 P 值分别为 0.0915、0.0312、0.0006 和 0.0006。结论利用 SARS-CoV2 穗状病毒（S1）和 ACE2 蛋白进行的体外分析证明，NS 种子提取物具有抑制 S-ACE2 相互作用的潜力，值得进一步研究，从而发现治疗 SARS-CoV2 感染的潜在药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.